Scarica l'app Stockscreener
23.81
2.58%
-0.63
Dopo l'orario di chiusura:
23.79
-0.02
-0.08%
Precedente Chiudi:
$24.44
Aprire:
$24.1
Volume 24 ore:
88,624
Relative Volume:
1.09
Capitalizzazione di mercato:
$263.34M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-0.08%
1M Prestazione:
-2.66%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$22.78
$24.94
Intervallo di 1 settimana:
$22.78
$26.74
Portata 52W:
$11.17
$29.27
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
125 STRAFFORD AVE, WAYNE
Confronta PVLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
23.81 | 263.46M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Palvella Therapeutics Advances in Rare Skin Disease Therapies - TipRanks
A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - simplywall.st
Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MyChesCo
Palvella Therapeutics Strengthens Executive Leadership Team - GlobeNewswire
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer - Investing.com
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer By Investing.com - Investing.com India
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer - The Manila Times
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease ... - Eagle-Tribune
Palvella Taps Rare Disease Star Who Led $500M Oxervate Launch for Upcoming Genetic Disease Treatment - Stock Titan
Brokers Set Expectations for PVLA FY2025 Earnings - Defense World
Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress - MSN
Canaccord Genuity Group Has Lowered Expectations for Palvella Therapeutics (NASDAQ:PVLA) Stock Price - Defense World
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MSN
Analysts Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $44.43 - Defense World
Palvella Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Palvella Therapeutics: Q1 Earnings Snapshot - CT Insider
Earnings call transcript: Palvella Therapeutics reports Q1 2025 loss, stock dips - Investing.com Nigeria
Palvella Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Palvella Therapeutics Reports Strong Q1 Financial Results - TipRanks
PALVELLA THERAPEUTICS Earnings Results: $PVLA Reports Quarterly Earnings - Nasdaq
PALVELLA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Palvella's Breakthrough Skin Disease Treatment Hits Major Milestone as Phase 3 Trial Surpasses Target - Stock Titan
Palvella Therapeutics (PVLA) Projected to Post Quarterly Earnings on Thursday - Defense World
Palvella Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Palvella Therapeutics Rings the Opening Bell - Nasdaq
Palvella Therapeutics to Ring Nasdaq Opening Bell - MyChesCo
Palvella Therapeutics to Host First Quarter 2025 Financial - GlobeNewswire
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 - The Manila Times
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update ... - Bluefield Daily Telegraph
Renaissance Technologies LLC Buys New Holdings in Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 - GlobeNewswire
Leading Rare Skin Disease Biotech Palvella Makes Nasdaq Debut with Opening Bell Ceremony - Stock Titan
Geode Capital Management LLC Invests $171,000 in Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MyChesCo
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo
Form DEF 14A PALVELLA THERAPEUTICS, For: Jun 10 - StreetInsider
Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025 - Yahoo Finance
Palvella Therapeutics to Present Key Findings on Lymphatic Malformations at Dermatology Conference - MyChesCo
One Palvella Therapeutics Insider Raised Their Stake In The Previous Year - Yahoo Finance
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Non sono disponibili dati finanziari per Palvella Therapeutics Inc (PVLA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):